<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1016/S1569-9056(19)34604-4</dc:identifier><dc:language>eng</dc:language><dc:creator>Rubio Briones, José</dc:creator><dc:creator>Borque Fernando, Ángel</dc:creator><dc:creator>Esteban Escaño, Luis Mariano</dc:creator><dc:creator>Martínez Breijo, Sara</dc:creator><dc:creator>Llorente, Carlos</dc:creator><dc:creator>Medina, R</dc:creator><dc:creator>Mallén Mateo, E</dc:creator><dc:creator>Sanguedolce, F</dc:creator><dc:creator>Gómez E.</dc:creator><dc:title>Types of pathological progression within Spanish Register on Active Surveillance and their relevance in radical prostatectomy specimens</dc:title><dc:identifier>ART-2019-115138</dc:identifier><dc:description>Resumen presentado en: 11th European Multidisciplinary Congress on Urological Cancers (EMUC19)
In active surveillance (AS) management, there are controversies for the different pathological progression (PP) criteria from prostate cancer (PCa) GGI (Gleason 3+3). Our objective is to know if PP just in tumoral volumen is irrelevant vs PP in grade...</dc:description><dc:date>2019</dc:date><dc:source>http://zaguan.unizar.es/record/96141</dc:source><dc:doi>10.1016/S1569-9056(19)34604-4</dc:doi><dc:identifier>http://zaguan.unizar.es/record/96141</dc:identifier><dc:identifier>oai:zaguan.unizar.es:96141</dc:identifier><dc:identifier.citation>EUROPEAN UROLOGY SUPPLEMENTS 18 , 11 (2019), e3434-e3435</dc:identifier.citation><dc:rights>by-nc-nd</dc:rights><dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>